The potential role and rationale for treatment of heart failure with sodium–glucose co‐transporter 2 inhibitors

• Published in: European journal of heart failure Vol. 19; no. 11; pp. 1390 - 1400
• Main Authors: Butler, Javed, Hamo, Carine E., Filippatos, Gerasimos, Pocock, Stuart J., Bernstein, Richard A., Brueckmann, Martina, Cheung, Alfred K., George, Jyothis T., Green, Jennifer B., Januzzi, James L., Kaul, Sanjay, Lam, Carolyn S.P., Lip, Gregory Y.H., Marx, Nikolaus, McCullough, Peter A., Mehta, Cyrus R., Ponikowski, Piotr, Rosenstock, Julio, Sattar, Naveed, Salsali, Afshin, Scirica, Benjamin M., Shah, Sanjiv J., Tsutsui, Hiroyuki, Verma, Subodh, Wanner, Christoph, Woerle, Hans‐Juergan, Zannad, Faiez, Anker, Stefan D.
• Format: Journal Article
• Language: English
• Published: Oxford, UK John Wiley & Sons, Ltd 01.11.2017
• Subjects: Benzhydryl Compounds - therapeutic use; Diabetes mellitus; Empagliflozin; Glucosides - therapeutic use; Heart failure; Heart Failure - drug therapy; Humans; Hypoglycemic Agents - therapeutic use; SGLT2 inhibitors; Sodium; Sodium-Glucose Transporter 2 - antagonists & inhibitors; Treatment Outcome; Heart failure; Empagliflozin; Diabetes mellitus; SGLT2 inhibitors

Heart failure (HF) and type 2 diabetes mellitus (T2DM) are both growing public health concerns contributing to major medical and economic burdens to society. T2DM increases the risk of HF, frequently occurs concomitantly with HF, and worsens the prognosis of HF. Several anti‐hyperglycaemic medicatio...